See more : Bata India Limited (BATAINDIA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Lipella Pharmaceuticals Inc. (LIPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lipella Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bobst Group SA (BOBNN.SW) Income Statement Analysis – Financial Results
- Gram Car Carriers ASA (GCC.OL) Income Statement Analysis – Financial Results
- Tech and Energy Transition Corporation (TETC) Income Statement Analysis – Financial Results
- Teradata Corporation (0LEE.L) Income Statement Analysis – Financial Results
- Lekoil Limited (LEK.L) Income Statement Analysis – Financial Results
Lipella Pharmaceuticals Inc. (LIPO)
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 449.62K | 184.16K | 259.35K | 961.68K | 694.75K |
| Cost of Revenue | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| Gross Profit | -2.59M | -2.36M | -1.20M | -14.28K | 11.86K |
| Gross Profit Ratio | -575.87% | -1,283.43% | -461.71% | -1.48% | 1.71% |
| Research & Development | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| General & Administrative | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Other Expenses | 0.00 | -45.00 | 57.09K | 0.00 | 0.00 |
| Operating Expenses | 2.16M | 2.77M | 2.18M | 1.02M | 748.54K |
| Cost & Expenses | 5.20M | 2.77M | 2.18M | 1.02M | 748.54K |
| Interest Income | 137.84K | 1.68K | 104.00 | 3.17K | 334.00 |
| Interest Expense | 10.85K | 9.61K | 6.83K | 7.97K | 8.39K |
| Depreciation & Amortization | 1.69K | 2.59M | 1.92M | 56.86K | 53.79K |
| EBITDA | -4.61M | -2.59M | 0.00 | -53.69K | 334.00 |
| EBITDA Ratio | -1,024.52% | -1,405.37% | -716.66% | -5.58% | -7.74% |
| Operating Income | -4.75M | -2.59M | -1.92M | -56.86K | -53.79K |
| Operating Income Ratio | -1,055.55% | -1,406.26% | -738.71% | -5.91% | -7.74% |
| Total Other Income/Expenses | 126.99K | -7.98K | 50.36K | -4.79K | -8.06K |
| Income Before Tax | -4.62M | -2.60M | -1.87M | -61.66K | -61.85K |
| Income Before Tax Ratio | -1,027.31% | -1,410.59% | -719.30% | -6.41% | -8.90% |
| Income Tax Expense | 0.00 | -1.63K | 6.73K | 4.79K | -53.79K |
| Net Income | -4.62M | -2.60M | -1.87M | -66.45K | -61.85K |
| Net Income Ratio | -1,027.31% | -1,409.71% | -721.89% | -6.91% | -8.90% |
| EPS | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| EPS Diluted | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
| Weighted Avg Shares Out (Dil) | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 American Society of...
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food...
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBA Pittsburgh, PA, April 17, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise.
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Pittsburgh, PA, April 05, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American...
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024...
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Pittsburgh, PA, April 03, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has...
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Clinical testing of LP-410 expected to commence in Q2 2024 Pittsburgh, PA, March 05, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces...
Source: https://incomestatements.info
Category: Stock Reports